OptimizeRx Corporation OPRX
8.95 USD -0.40 (-4.28%)
At closeNov 11, 2026, 7:55 PM EST
7.15 -1.80 -20.11%
After hours · Nov 11, 7:55 PM ET
8.85 Day range 9.83
4.54 52-week range 16.37
- YTD
- -27.00%
- 1 year
- -43.68%
News
seekingalpha.com OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
marketbeat.com What OptimizeRx (OPRX) Said on Its Q3 Earnings Call OptimizeRx NASDAQ: OPRX lowered its 2026 revenue outlook after third-quarter sales fell 17%, even as cost reductions and a favorable product mix helped the healthcare marketing technology company…
zacks.com OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.2 per share a year ago.
benzinga.com OptimizeRx Q3 2026 Earnings Call Transcript OptimizeRx (NASDAQ:OPRX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
benzinga.com OptimizeRx Q3 Adj. EPS $0.20 Beats $0.17 Estimate, Sales $21.615M Beat $21.188M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is unchanged from the same period last year. The…
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $95.000M-$100.000M to $87.000M-$93.000M vs $96.230M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.
globenewswire.com OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
globenewswire.com OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
globenewswire.com OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care…- benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
zacks.com Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
globenewswire.com OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare…
seekingalpha.com OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic…
defenseworld.net Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON) OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies…
globenewswire.com OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence New functionality helps DSPs and agency planners create deterministic HCP and consumer audiences faster, using one single workflow New functionality helps DSPs and agency planners create…
globenewswire.com OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
globenewswire.com OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…
defenseworld.net AWM Investment Company Inc. Invests $1.38 Million in OptimizeRx Corp. $OPRX AWM Investment Company Inc. acquired a new stake in OptimizeRx Corp. (NASDAQ: OPRX) in the undefined quarter, according to the company in its most recent filing with the SEC. The firm acquired…
benzinga.com Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11 Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
defenseworld.net Dimensional Fund Advisors LP Purchases 102,661 Shares of OptimizeRx Corp. $OPRX Dimensional Fund Advisors LP grew its position in shares of OptimizeRx Corp. (NASDAQ: OPRX) by 22.3% during the undefined quarter, according to the company in its most recent filing with the…
marketbeat.com OptimizeRx Q2 Earnings Call Highlights OptimizeRx NASDAQ: OPRX reported second-quarter fiscal 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, while adjusted EBITDA totaled $4.9 million, management said on its…
seekingalpha.com OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript OptimizeRx Corporation (OPRX) Q2 2026 Earnings Call Transcript
zacks.com OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago.
benzinga.com OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
benzinga.com OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24…
globenewswire.com OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth The Company Names Andy D'Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027
globenewswire.com OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance – Q2 revenue totals $20.5 million– Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively– Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted…
benzinga.com OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at…- benzinga.com OptimizeRx's Electronic Health Record Network Integrated By DeepIntent OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important…
- benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $20 to $11.
- benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
- benzinga.com OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session 
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.- benzinga.com OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $20 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $24 to $20.
benzinga.com OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 forecasts due to cautious spending.
benzinga.com Assessing OptimizeRx: Insights From 4 Financial Analysts 
benzinga.com Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18 Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11 B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.
- benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $10 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.